Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation

Published:2011-04 Issue:4 Volume:17 Page:497-506
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Palomo Marta,Diaz-Ricart Maribel,Rovira Montserrat,Escolar Ginés,Carreras Enric

Funder

FIS

German José Carreras Leukaemia Foundation

SAF

Red HERACLES, Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference39 articles.

1. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009;Ljungman;Bone Marrow Transplant,2010

2. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms;Palomo;Biol Blood Marrow Transplant,2009

3. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation;Palomo;Biol Blood Marrow Transplant,2010

4. Spatial and temporal dynamics of the endothelium;Aird;J Thromb Haemost,2005

5. Endothelial cell activation. A central pathophysiological process;Hunt;BMJ,1998

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell Transplantation (HCT);Transplantation and Cellular Therapy;2024-07

2. sVEGF-R1 in acute non-infectious toxicity syndromes after pediatric allogeneic hematopoietic stem cell transplantation;Transplant Immunology;2024-02

3. A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome;Blood Advances;2023-11-14

4. Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome;Frontiers in Immunology;2023-06-27

5. Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study;Transplantation and Cellular Therapy;2023-06